<DOC>
	<DOCNO>NCT00478985</DOCNO>
	<brief_summary>The first purpose study evaluate persistence complete molecular remission patient Chronic Myeloid Leukemia stop imatinib treatment ( determine Reverse Transcription real-time Polymerase Chain Reaction ( RT-PCR ) negative bcr-abl transcript ) . The second purpose determine clinicals biologicals factor associate persistent complete molecular remission .</brief_summary>
	<brief_title>Evaluation Persistence Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia</brief_title>
	<detailed_description>Principal Objective : To evaluate complete molecular remission persistence stop imatinib six month measure RT-PCR negative bcr-abl transcript patient Chronic Myeloid Leukemia . Secondary Objective : - To determine clinicals factor associate complete molecular remission stop imatinib patient Chronic Myeloid Leukemia . - To determine biologics factor ( immunologic molecular ) associate complete molecular remission stop imatinib patient Chronic Myeloid Leukaemia . - To determine molecular relapse level six month persistent complete molecular remission without imatinib . - To determine complete molecular remission length . - To evaluate medical economical impact stop imatinib treatment . Study design : multicentric trial</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients must reach 18th birthday Women childbearing potential must agree use effective method contraception Patients must affiliate social security regime Patients must receive imatinib therapy least 36 month . Patients must complete molecular remission least two consecutive year least five RTPCR negative measure bcrabl transcript . Patients must HIV , HCV HBV negative Patients molecular followup realize accordance international recommendation All patient must inform investigational nature study must sign give write informed consent . Patients protected law . Patients unable give consent participate study . Patients pathologies treatment able enhance potential relapse risk stop imatinib . Patients pathologies treatment able interfere immunologic study ( except IFN Î± ) : Corticosteroids immuno suppressor Other concomitant malign pathology treat chemotherapy radiotherapy Previous program Haematopoietic Stem Cell allogreffe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Adult Chronic</keyword>
	<keyword>Myeloid</keyword>
</DOC>